Loading clinical trials...
Loading clinical trials...
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travopr...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Allergan
NCT07539675 · Primary Angle-Closure Glaucoma
NCT06289491 · Glaucoma, Glaucoma, Open-Angle
NCT07496957 · GLAUCOMA 1, OPEN ANGLE, D (Disorder)
NCT04354545 · Glaucoma, Ocular Surface Disease
NCT07455786 · Glaucoma
San Diego, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions